nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—CYP2C18—Ifosfamide—testicular cancer	0.163	0.241	CbGbCtD
Imipramine—CYP3A7—Ifosfamide—testicular cancer	0.0542	0.0802	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0542	0.0802	CbGbCtD
Imipramine—SLC22A2—Vinblastine—testicular cancer	0.0527	0.078	CbGbCtD
Imipramine—CYP2B6—Ifosfamide—testicular cancer	0.0516	0.0764	CbGbCtD
Imipramine—SLC22A2—Cisplatin—testicular cancer	0.0483	0.0716	CbGbCtD
Imipramine—CYP2C19—Ifosfamide—testicular cancer	0.0328	0.0485	CbGbCtD
Imipramine—ADRA1B—vas deferens—testicular cancer	0.0293	0.308	CbGeAlD
Imipramine—CYP2B6—Cisplatin—testicular cancer	0.0251	0.0371	CbGbCtD
Imipramine—CYP2E1—Etoposide—testicular cancer	0.025	0.037	CbGbCtD
Imipramine—ABCB1—Dactinomycin—testicular cancer	0.0224	0.0332	CbGbCtD
Imipramine—HTR7—vas deferens—testicular cancer	0.017	0.179	CbGeAlD
Imipramine—CYP2B6—Doxorubicin—testicular cancer	0.0168	0.0249	CbGbCtD
Imipramine—CYP3A4—Ifosfamide—testicular cancer	0.0158	0.0235	CbGbCtD
Imipramine—CYP1A2—Etoposide—testicular cancer	0.0144	0.0214	CbGbCtD
Imipramine—ABCB1—Vinblastine—testicular cancer	0.014	0.0208	CbGbCtD
Imipramine—CYP2D6—Vinblastine—testicular cancer	0.0132	0.0196	CbGbCtD
Imipramine—ABCB1—Cisplatin—testicular cancer	0.0129	0.019	CbGbCtD
Imipramine—ABCB1—Etoposide—testicular cancer	0.0126	0.0187	CbGbCtD
Imipramine—ABCB1—Doxorubicin—testicular cancer	0.00862	0.0128	CbGbCtD
Imipramine—CYP3A4—Vinblastine—testicular cancer	0.0084	0.0124	CbGbCtD
Imipramine—ABCB1—Methotrexate—testicular cancer	0.00835	0.0124	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—testicular cancer	0.00812	0.012	CbGbCtD
Imipramine—CYP3A4—Etoposide—testicular cancer	0.00757	0.0112	CbGbCtD
Imipramine—HTR7—vein—testicular cancer	0.00724	0.0761	CbGeAlD
Imipramine—CYP3A4—Doxorubicin—testicular cancer	0.00516	0.00765	CbGbCtD
Imipramine—HTR2A—vein—testicular cancer	0.00452	0.0475	CbGeAlD
Imipramine—KCND2—female gonad—testicular cancer	0.00219	0.023	CbGeAlD
Imipramine—KCND2—testis—testicular cancer	0.00194	0.0204	CbGeAlD
Imipramine—SLC22A4—seminal vesicle—testicular cancer	0.00171	0.018	CbGeAlD
Imipramine—KCND3—testis—testicular cancer	0.00169	0.0178	CbGeAlD
Imipramine—SLC22A3—embryo—testicular cancer	0.00166	0.0174	CbGeAlD
Imipramine—CHRM4—testis—testicular cancer	0.00161	0.0169	CbGeAlD
Imipramine—SLC22A3—seminal vesicle—testicular cancer	0.00156	0.0164	CbGeAlD
Imipramine—KCND3—lymph node—testicular cancer	0.00123	0.0129	CbGeAlD
Imipramine—KCNH2—seminal vesicle—testicular cancer	0.0012	0.0126	CbGeAlD
Imipramine—SLC22A3—gonad—testicular cancer	0.00113	0.0118	CbGeAlD
Imipramine—SLC6A2—gonad—testicular cancer	0.000965	0.0101	CbGeAlD
Imipramine—HTR7—gonad—testicular cancer	0.00093	0.00978	CbGeAlD
Imipramine—CYP2E1—seminal vesicle—testicular cancer	0.000924	0.00971	CbGeAlD
Imipramine—SLC22A3—female gonad—testicular cancer	0.000916	0.00962	CbGeAlD
Imipramine—SLC6A3—testis—testicular cancer	0.000862	0.00907	CbGeAlD
Imipramine—HTR2A—embryo—testicular cancer	0.000855	0.00899	CbGeAlD
Imipramine—SLC22A3—testis—testicular cancer	0.000812	0.00854	CbGeAlD
Imipramine—CHRM3—female gonad—testicular cancer	0.000794	0.00835	CbGeAlD
Imipramine—CYP2B6—gonad—testicular cancer	0.000711	0.00748	CbGeAlD
Imipramine—CHRM3—testis—testicular cancer	0.000705	0.00741	CbGeAlD
Imipramine—KCNH2—female gonad—testicular cancer	0.000704	0.0074	CbGeAlD
Imipramine—SLC6A2—testis—testicular cancer	0.000696	0.00731	CbGeAlD
Imipramine—ORM1—lymph node—testicular cancer	0.000672	0.00707	CbGeAlD
Imipramine—HTR7—testis—testicular cancer	0.000671	0.00705	CbGeAlD
Imipramine—SLC22A4—lymph node—testicular cancer	0.000647	0.0068	CbGeAlD
Imipramine—DRD2—testis—testicular cancer	0.000634	0.00666	CbGeAlD
Imipramine—KCNH2—testis—testicular cancer	0.000625	0.00657	CbGeAlD
Imipramine—SLC22A3—lymph node—testicular cancer	0.000589	0.00619	CbGeAlD
Imipramine—HTR2A—gonad—testicular cancer	0.00058	0.0061	CbGeAlD
Imipramine—HRH1—female gonad—testicular cancer	0.000565	0.00593	CbGeAlD
Imipramine—ABCB1—embryo—testicular cancer	0.00056	0.00589	CbGeAlD
Imipramine—ABCB1—seminal vesicle—testicular cancer	0.000526	0.00553	CbGeAlD
Imipramine—CYP2B6—testis—testicular cancer	0.000513	0.00539	CbGeAlD
Imipramine—SLC6A2—lymph node—testicular cancer	0.000504	0.0053	CbGeAlD
Imipramine—HRH1—testis—testicular cancer	0.000501	0.00526	CbGeAlD
Imipramine—SLC22A4—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000501	0.0531	CbGpPWpGaD
Imipramine—CYP2E1—testis—testicular cancer	0.000481	0.00506	CbGeAlD
Imipramine—KCNH2—lymph node—testicular cancer	0.000453	0.00476	CbGeAlD
Imipramine—CYP2D6—female gonad—testicular cancer	0.00043	0.00452	CbGeAlD
Imipramine—HTR2A—testis—testicular cancer	0.000418	0.0044	CbGeAlD
Imipramine—CYP2D6—testis—testicular cancer	0.000381	0.004	CbGeAlD
Imipramine—ABCB1—gonad—testicular cancer	0.00038	0.004	CbGeAlD
Imipramine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000378	0.04	CbGpPWpGaD
Imipramine—HRH1—lymph node—testicular cancer	0.000363	0.00382	CbGeAlD
Imipramine—ABCB1—female gonad—testicular cancer	0.000309	0.00325	CbGeAlD
Imipramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000294	0.0312	CbGpPWpGaD
Imipramine—ABCB1—testis—testicular cancer	0.000274	0.00288	CbGeAlD
Imipramine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.00026	0.0276	CbGpPWpGaD
Imipramine—SLC6A4—NRF2 pathway—SLC2A6—testicular cancer	0.000246	0.0261	CbGpPWpGaD
Imipramine—Rash—Bleomycin—testicular cancer	0.000243	0.00111	CcSEcCtD
Imipramine—Dermatitis—Bleomycin—testicular cancer	0.000243	0.0011	CcSEcCtD
Imipramine—Stomatitis—Methotrexate—testicular cancer	0.000239	0.00108	CcSEcCtD
Imipramine—Pollakiuria—Epirubicin—testicular cancer	0.000237	0.00108	CcSEcCtD
Imipramine—Asthenia—Ifosfamide—testicular cancer	0.000237	0.00107	CcSEcCtD
Imipramine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000237	0.0251	CbGpPWpGaD
Imipramine—Eosinophilia—Doxorubicin—testicular cancer	0.000235	0.00107	CcSEcCtD
Imipramine—Photosensitivity reaction—Epirubicin—testicular cancer	0.000235	0.00106	CcSEcCtD
Imipramine—Feeling abnormal—Cisplatin—testicular cancer	0.000234	0.00106	CcSEcCtD
Imipramine—Paraesthesia—Etoposide—testicular cancer	0.000234	0.00106	CcSEcCtD
Imipramine—Weight increased—Epirubicin—testicular cancer	0.000234	0.00106	CcSEcCtD
Imipramine—Pruritus—Ifosfamide—testicular cancer	0.000234	0.00106	CcSEcCtD
Imipramine—Weight decreased—Epirubicin—testicular cancer	0.000232	0.00106	CcSEcCtD
Imipramine—Somnolence—Etoposide—testicular cancer	0.000232	0.00105	CcSEcCtD
Imipramine—Hepatobiliary disease—Methotrexate—testicular cancer	0.000232	0.00105	CcSEcCtD
Imipramine—Nausea—Bleomycin—testicular cancer	0.000229	0.00104	CcSEcCtD
Imipramine—Infestation—Epirubicin—testicular cancer	0.000229	0.00104	CcSEcCtD
Imipramine—Infestation NOS—Epirubicin—testicular cancer	0.000229	0.00104	CcSEcCtD
Imipramine—Drowsiness—Epirubicin—testicular cancer	0.000229	0.00104	CcSEcCtD
Imipramine—Vomiting—Dactinomycin—testicular cancer	0.000229	0.00104	CcSEcCtD
Imipramine—Agranulocytosis—Methotrexate—testicular cancer	0.000228	0.00104	CcSEcCtD
Imipramine—SLC22A4—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000227	0.0241	CbGpPWpGaD
Imipramine—Rash—Dactinomycin—testicular cancer	0.000227	0.00103	CcSEcCtD
Imipramine—Decreased appetite—Etoposide—testicular cancer	0.000227	0.00103	CcSEcCtD
Imipramine—Diarrhoea—Ifosfamide—testicular cancer	0.000226	0.00103	CcSEcCtD
Imipramine—Pancytopenia—Doxorubicin—testicular cancer	0.000226	0.00102	CcSEcCtD
Imipramine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000225	0.00102	CcSEcCtD
Imipramine—Body temperature increased—Cisplatin—testicular cancer	0.000225	0.00102	CcSEcCtD
Imipramine—Fatigue—Etoposide—testicular cancer	0.000225	0.00102	CcSEcCtD
Imipramine—Neuropathy peripheral—Epirubicin—testicular cancer	0.000225	0.00102	CcSEcCtD
Imipramine—Jaundice—Epirubicin—testicular cancer	0.000223	0.00101	CcSEcCtD
Imipramine—Stomatitis—Epirubicin—testicular cancer	0.000223	0.00101	CcSEcCtD
Imipramine—Constipation—Etoposide—testicular cancer	0.000223	0.00101	CcSEcCtD
Imipramine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000221	0.0234	CbGpPWpGaD
Imipramine—Hepatitis—Methotrexate—testicular cancer	0.00022	0.000998	CcSEcCtD
Imipramine—Pollakiuria—Doxorubicin—testicular cancer	0.00022	0.000997	CcSEcCtD
Imipramine—HTR6—G alpha (s) signalling events—INSL3—testicular cancer	0.000219	0.0232	CbGpPWpGaD
Imipramine—HTR7—G alpha (s) signalling events—INSL3—testicular cancer	0.000219	0.0232	CbGpPWpGaD
Imipramine—Dizziness—Ifosfamide—testicular cancer	0.000218	0.000991	CcSEcCtD
Imipramine—Urinary tract disorder—Methotrexate—testicular cancer	0.000217	0.000985	CcSEcCtD
Imipramine—Photosensitivity reaction—Doxorubicin—testicular cancer	0.000217	0.000985	CcSEcCtD
Imipramine—Hepatobiliary disease—Epirubicin—testicular cancer	0.000217	0.000984	CcSEcCtD
Imipramine—Weight increased—Doxorubicin—testicular cancer	0.000216	0.000982	CcSEcCtD
Imipramine—Urethral disorder—Methotrexate—testicular cancer	0.000215	0.000978	CcSEcCtD
Imipramine—Weight decreased—Doxorubicin—testicular cancer	0.000215	0.000976	CcSEcCtD
Imipramine—Feeling abnormal—Etoposide—testicular cancer	0.000215	0.000975	CcSEcCtD
Imipramine—Nausea—Dactinomycin—testicular cancer	0.000214	0.000971	CcSEcCtD
Imipramine—Agranulocytosis—Epirubicin—testicular cancer	0.000214	0.000971	CcSEcCtD
Imipramine—Gastrointestinal pain—Etoposide—testicular cancer	0.000213	0.000968	CcSEcCtD
Imipramine—Infestation—Doxorubicin—testicular cancer	0.000212	0.000962	CcSEcCtD
Imipramine—Drowsiness—Doxorubicin—testicular cancer	0.000212	0.000962	CcSEcCtD
Imipramine—Infestation NOS—Doxorubicin—testicular cancer	0.000212	0.000962	CcSEcCtD
Imipramine—SLC6A2—NRF2 pathway—SLC2A6—testicular cancer	0.000212	0.0225	CbGpPWpGaD
Imipramine—Vomiting—Ifosfamide—testicular cancer	0.00021	0.000953	CcSEcCtD
Imipramine—Rash—Ifosfamide—testicular cancer	0.000208	0.000945	CcSEcCtD
Imipramine—Dermatitis—Ifosfamide—testicular cancer	0.000208	0.000944	CcSEcCtD
Imipramine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000208	0.000943	CcSEcCtD
Imipramine—Urticaria—Etoposide—testicular cancer	0.000207	0.00094	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—testicular cancer	0.000207	0.000938	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—testicular cancer	0.000207	0.000938	CcSEcCtD
Imipramine—Body temperature increased—Etoposide—testicular cancer	0.000206	0.000935	CcSEcCtD
Imipramine—Abdominal pain—Etoposide—testicular cancer	0.000206	0.000935	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—testicular cancer	0.000206	0.000934	CcSEcCtD
Imipramine—Eye disorder—Methotrexate—testicular cancer	0.000205	0.000932	CcSEcCtD
Imipramine—Tinnitus—Methotrexate—testicular cancer	0.000205	0.00093	CcSEcCtD
Imipramine—Hypoaesthesia—Epirubicin—testicular cancer	0.000205	0.000929	CcSEcCtD
Imipramine—Asthenia—Cisplatin—testicular cancer	0.000204	0.000927	CcSEcCtD
Imipramine—Cardiac disorder—Methotrexate—testicular cancer	0.000204	0.000926	CcSEcCtD
Imipramine—Urinary tract disorder—Epirubicin—testicular cancer	0.000203	0.000922	CcSEcCtD
Imipramine—Urethral disorder—Epirubicin—testicular cancer	0.000202	0.000915	CcSEcCtD
Imipramine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.0002	0.00091	CcSEcCtD
Imipramine—Angiopathy—Methotrexate—testicular cancer	0.000199	0.000905	CcSEcCtD
Imipramine—ABCB1—lymph node—testicular cancer	0.000199	0.00209	CbGeAlD
Imipramine—Immune system disorder—Methotrexate—testicular cancer	0.000199	0.000901	CcSEcCtD
Imipramine—Mediastinal disorder—Methotrexate—testicular cancer	0.000198	0.000899	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—testicular cancer	0.000198	0.000898	CcSEcCtD
Imipramine—Nausea—Ifosfamide—testicular cancer	0.000196	0.00089	CcSEcCtD
Imipramine—Diarrhoea—Cisplatin—testicular cancer	0.000195	0.000884	CcSEcCtD
Imipramine—Alopecia—Methotrexate—testicular cancer	0.000194	0.000882	CcSEcCtD
Imipramine—Mental disorder—Methotrexate—testicular cancer	0.000193	0.000874	CcSEcCtD
Imipramine—Eye disorder—Epirubicin—testicular cancer	0.000192	0.000873	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—testicular cancer	0.000192	0.000871	CcSEcCtD
Imipramine—Malnutrition—Methotrexate—testicular cancer	0.000191	0.000869	CcSEcCtD
Imipramine—Flushing—Epirubicin—testicular cancer	0.000191	0.000867	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—testicular cancer	0.000191	0.000867	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—testicular cancer	0.00019	0.000864	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000189	0.00086	CcSEcCtD
Imipramine—KCNH2—Hematopoietic Stem Cell Differentiation—KITLG—testicular cancer	0.000188	0.0199	CbGpPWpGaD
Imipramine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000188	0.000853	CcSEcCtD
Imipramine—SLC6A3—NRF2 pathway—SLC2A6—testicular cancer	0.000188	0.0199	CbGpPWpGaD
Imipramine—Dysgeusia—Methotrexate—testicular cancer	0.000187	0.000851	CcSEcCtD
Imipramine—Asthenia—Etoposide—testicular cancer	0.000187	0.000849	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—testicular cancer	0.000187	0.000847	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—testicular cancer	0.000187	0.000847	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—testicular cancer	0.000186	0.000843	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—testicular cancer	0.000185	0.000841	CcSEcCtD
Imipramine—Pruritus—Etoposide—testicular cancer	0.000184	0.000837	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—testicular cancer	0.000184	0.000834	CcSEcCtD
Imipramine—Alopecia—Epirubicin—testicular cancer	0.000182	0.000825	CcSEcCtD
Imipramine—Vomiting—Cisplatin—testicular cancer	0.000181	0.000821	CcSEcCtD
Imipramine—Vision blurred—Methotrexate—testicular cancer	0.00018	0.000819	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—testicular cancer	0.00018	0.000818	CcSEcCtD
Imipramine—Rash—Cisplatin—testicular cancer	0.000179	0.000814	CcSEcCtD
Imipramine—Dermatitis—Cisplatin—testicular cancer	0.000179	0.000814	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—testicular cancer	0.000179	0.000813	CcSEcCtD
Imipramine—Diarrhoea—Etoposide—testicular cancer	0.000178	0.00081	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—testicular cancer	0.000178	0.000807	CcSEcCtD
Imipramine—Ill-defined disorder—Methotrexate—testicular cancer	0.000178	0.000806	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—testicular cancer	0.000177	0.000805	CcSEcCtD
Imipramine—Flushing—Doxorubicin—testicular cancer	0.000177	0.000802	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—testicular cancer	0.000177	0.000802	CcSEcCtD
Imipramine—Tension—Epirubicin—testicular cancer	0.000176	0.000798	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—testicular cancer	0.000175	0.000796	CcSEcCtD
Imipramine—Nervousness—Epirubicin—testicular cancer	0.000174	0.000789	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—testicular cancer	0.000173	0.000784	CcSEcCtD
Imipramine—Malaise—Methotrexate—testicular cancer	0.000173	0.000783	CcSEcCtD
Imipramine—Dizziness—Etoposide—testicular cancer	0.000172	0.000783	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—testicular cancer	0.000172	0.00078	CcSEcCtD
Imipramine—SLC22A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000172	0.0182	CbGpPWpGaD
Imipramine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000172	0.000779	CcSEcCtD
Imipramine—Leukopenia—Methotrexate—testicular cancer	0.000171	0.000777	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—testicular cancer	0.00017	0.000772	CcSEcCtD
Imipramine—Nausea—Cisplatin—testicular cancer	0.000169	0.000767	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—testicular cancer	0.000169	0.000766	CcSEcCtD
Imipramine—Alopecia—Doxorubicin—testicular cancer	0.000168	0.000763	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—testicular cancer	0.000167	0.000757	CcSEcCtD
Imipramine—Ill-defined disorder—Epirubicin—testicular cancer	0.000166	0.000754	CcSEcCtD
Imipramine—Convulsion—Methotrexate—testicular cancer	0.000166	0.000752	CcSEcCtD
Imipramine—Vomiting—Etoposide—testicular cancer	0.000166	0.000752	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—testicular cancer	0.000166	0.000752	CcSEcCtD
Imipramine—Agitation—Epirubicin—testicular cancer	0.000165	0.000747	CcSEcCtD
Imipramine—Rash—Etoposide—testicular cancer	0.000164	0.000746	CcSEcCtD
Imipramine—Dermatitis—Etoposide—testicular cancer	0.000164	0.000745	CcSEcCtD
Imipramine—Headache—Etoposide—testicular cancer	0.000163	0.000741	CcSEcCtD
Imipramine—Tension—Doxorubicin—testicular cancer	0.000163	0.000738	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—testicular cancer	0.000162	0.000736	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000162	0.000734	CcSEcCtD
Imipramine—Malaise—Epirubicin—testicular cancer	0.000161	0.000733	CcSEcCtD
Imipramine—Discomfort—Methotrexate—testicular cancer	0.000161	0.000731	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—testicular cancer	0.000161	0.00073	CcSEcCtD
Imipramine—Syncope—Epirubicin—testicular cancer	0.000161	0.000729	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—testicular cancer	0.00016	0.000728	CcSEcCtD
Imipramine—Palpitations—Epirubicin—testicular cancer	0.000158	0.000718	CcSEcCtD
Imipramine—Confusional state—Methotrexate—testicular cancer	0.000157	0.000715	CcSEcCtD
Imipramine—Loss of consciousness—Epirubicin—testicular cancer	0.000157	0.000714	CcSEcCtD
Imipramine—Anaphylactic shock—Methotrexate—testicular cancer	0.000156	0.000709	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—testicular cancer	0.000156	0.000709	CcSEcCtD
Imipramine—Convulsion—Epirubicin—testicular cancer	0.000155	0.000704	CcSEcCtD
Imipramine—Infection—Methotrexate—testicular cancer	0.000155	0.000704	CcSEcCtD
Imipramine—Nausea—Etoposide—testicular cancer	0.000155	0.000703	CcSEcCtD
Imipramine—Hypertension—Epirubicin—testicular cancer	0.000155	0.000702	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000154	0.000698	CcSEcCtD
Imipramine—Nervous system disorder—Methotrexate—testicular cancer	0.000153	0.000695	CcSEcCtD
Imipramine—Thrombocytopenia—Methotrexate—testicular cancer	0.000153	0.000694	CcSEcCtD
Imipramine—Agitation—Doxorubicin—testicular cancer	0.000152	0.000691	CcSEcCtD
Imipramine—Anxiety—Epirubicin—testicular cancer	0.000152	0.00069	CcSEcCtD
Imipramine—Skin disorder—Methotrexate—testicular cancer	0.000152	0.000688	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000151	0.000687	CcSEcCtD
Imipramine—Hyperhidrosis—Methotrexate—testicular cancer	0.000151	0.000685	CcSEcCtD
Imipramine—Discomfort—Epirubicin—testicular cancer	0.000151	0.000684	CcSEcCtD
Imipramine—Malaise—Doxorubicin—testicular cancer	0.000149	0.000678	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—testicular cancer	0.000149	0.000677	CcSEcCtD
Imipramine—Anorexia—Methotrexate—testicular cancer	0.000149	0.000676	CcSEcCtD
Imipramine—Syncope—Doxorubicin—testicular cancer	0.000149	0.000674	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—testicular cancer	0.000148	0.000673	CcSEcCtD
Imipramine—Confusional state—Epirubicin—testicular cancer	0.000147	0.000669	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—testicular cancer	0.000146	0.000665	CcSEcCtD
Imipramine—Oedema—Epirubicin—testicular cancer	0.000146	0.000663	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—testicular cancer	0.000146	0.000663	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—testicular cancer	0.000146	0.000661	CcSEcCtD
Imipramine—Infection—Epirubicin—testicular cancer	0.000145	0.000659	CcSEcCtD
Imipramine—Shock—Epirubicin—testicular cancer	0.000144	0.000653	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—testicular cancer	0.000144	0.000652	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—testicular cancer	0.000143	0.000651	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—testicular cancer	0.000143	0.000649	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—testicular cancer	0.000143	0.000649	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—testicular cancer	0.000143	0.000647	CcSEcCtD
Imipramine—Skin disorder—Epirubicin—testicular cancer	0.000142	0.000644	CcSEcCtD
Imipramine—Hyperhidrosis—Epirubicin—testicular cancer	0.000141	0.000641	CcSEcCtD
Imipramine—Insomnia—Methotrexate—testicular cancer	0.000141	0.000641	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—testicular cancer	0.000141	0.000638	CcSEcCtD
Imipramine—Paraesthesia—Methotrexate—testicular cancer	0.00014	0.000636	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.00014	0.000636	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—testicular cancer	0.000139	0.000633	CcSEcCtD
Imipramine—Anorexia—Epirubicin—testicular cancer	0.000139	0.000632	CcSEcCtD
Imipramine—Somnolence—Methotrexate—testicular cancer	0.000139	0.00063	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—testicular cancer	0.000138	0.000626	CcSEcCtD
Imipramine—Dyspepsia—Methotrexate—testicular cancer	0.000137	0.000624	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—testicular cancer	0.000136	0.000619	CcSEcCtD
Imipramine—Decreased appetite—Methotrexate—testicular cancer	0.000136	0.000616	CcSEcCtD
Imipramine—Oedema—Doxorubicin—testicular cancer	0.000135	0.000614	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000135	0.000614	CcSEcCtD
Imipramine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000135	0.000612	CcSEcCtD
Imipramine—Fatigue—Methotrexate—testicular cancer	0.000135	0.000611	CcSEcCtD
Imipramine—Infection—Doxorubicin—testicular cancer	0.000134	0.00061	CcSEcCtD
Imipramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000133	0.0142	CbGpPWpGaD
Imipramine—Shock—Doxorubicin—testicular cancer	0.000133	0.000604	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—testicular cancer	0.000133	0.000602	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000132	0.000601	CcSEcCtD
Imipramine—Insomnia—Epirubicin—testicular cancer	0.000132	0.0006	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—testicular cancer	0.000132	0.000599	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—testicular cancer	0.000131	0.000596	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—testicular cancer	0.000131	0.000596	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000131	0.000593	CcSEcCtD
Imipramine—Somnolence—Epirubicin—testicular cancer	0.00013	0.00059	CcSEcCtD
Imipramine—Anorexia—Doxorubicin—testicular cancer	0.000129	0.000585	CcSEcCtD
Imipramine—Feeling abnormal—Methotrexate—testicular cancer	0.000129	0.000584	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—testicular cancer	0.000129	0.000584	CcSEcCtD
Imipramine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000128	0.00058	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—testicular cancer	0.000127	0.000577	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000126	0.000573	CcSEcCtD
Imipramine—Fatigue—Epirubicin—testicular cancer	0.000126	0.000572	CcSEcCtD
Imipramine—Constipation—Epirubicin—testicular cancer	0.000125	0.000567	CcSEcCtD
Imipramine—Urticaria—Methotrexate—testicular cancer	0.000124	0.000563	CcSEcCtD
Imipramine—Abdominal pain—Methotrexate—testicular cancer	0.000123	0.00056	CcSEcCtD
Imipramine—Body temperature increased—Methotrexate—testicular cancer	0.000123	0.00056	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—testicular cancer	0.000122	0.000555	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—testicular cancer	0.000121	0.000551	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—testicular cancer	0.00012	0.000547	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—testicular cancer	0.00012	0.000546	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000119	0.000542	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—testicular cancer	0.000119	0.00054	CcSEcCtD
Imipramine—SLC6A3—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000118	0.0125	CbGpPWpGaD
Imipramine—Decreased appetite—Doxorubicin—testicular cancer	0.000118	0.000534	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000117	0.00053	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—testicular cancer	0.000117	0.000529	CcSEcCtD
Imipramine—Urticaria—Epirubicin—testicular cancer	0.000116	0.000527	CcSEcCtD
Imipramine—Constipation—Doxorubicin—testicular cancer	0.000116	0.000525	CcSEcCtD
Imipramine—SLC22A4—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000116	0.0123	CbGpPWpGaD
Imipramine—Abdominal pain—Epirubicin—testicular cancer	0.000116	0.000524	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—testicular cancer	0.000116	0.000524	CcSEcCtD
Imipramine—Asthenia—Methotrexate—testicular cancer	0.000112	0.000509	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—testicular cancer	0.000111	0.000506	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000111	0.000502	CcSEcCtD
Imipramine—Pruritus—Methotrexate—testicular cancer	0.00011	0.000501	CcSEcCtD
Imipramine—SLC22A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000108	0.0114	CbGpPWpGaD
Imipramine—Urticaria—Doxorubicin—testicular cancer	0.000107	0.000488	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—testicular cancer	0.000107	0.000485	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—testicular cancer	0.000107	0.000485	CcSEcCtD
Imipramine—Diarrhoea—Methotrexate—testicular cancer	0.000107	0.000485	CcSEcCtD
Imipramine—Asthenia—Epirubicin—testicular cancer	0.000105	0.000476	CcSEcCtD
Imipramine—HTR6—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000104	0.0111	CbGpPWpGaD
Imipramine—HTR7—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000104	0.0111	CbGpPWpGaD
Imipramine—Pruritus—Epirubicin—testicular cancer	0.000103	0.000469	CcSEcCtD
Imipramine—Dizziness—Methotrexate—testicular cancer	0.000103	0.000469	CcSEcCtD
Imipramine—SLC22A1—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.0001	0.0106	CbGpPWpGaD
Imipramine—Diarrhoea—Epirubicin—testicular cancer	0.0001	0.000454	CcSEcCtD
Imipramine—Vomiting—Methotrexate—testicular cancer	9.93e-05	0.000451	CcSEcCtD
Imipramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.85e-05	0.0104	CbGpPWpGaD
Imipramine—Rash—Methotrexate—testicular cancer	9.84e-05	0.000447	CcSEcCtD
Imipramine—Dermatitis—Methotrexate—testicular cancer	9.84e-05	0.000447	CcSEcCtD
Imipramine—Headache—Methotrexate—testicular cancer	9.78e-05	0.000444	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—testicular cancer	9.7e-05	0.00044	CcSEcCtD
Imipramine—Dizziness—Epirubicin—testicular cancer	9.66e-05	0.000439	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—testicular cancer	9.57e-05	0.000434	CcSEcCtD
Imipramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.43e-05	0.01	CbGpPWpGaD
Imipramine—Vomiting—Epirubicin—testicular cancer	9.29e-05	0.000422	CcSEcCtD
Imipramine—Nausea—Methotrexate—testicular cancer	9.27e-05	0.000421	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—testicular cancer	9.25e-05	0.00042	CcSEcCtD
Imipramine—Rash—Epirubicin—testicular cancer	9.21e-05	0.000418	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—testicular cancer	9.2e-05	0.000418	CcSEcCtD
Imipramine—Headache—Epirubicin—testicular cancer	9.15e-05	0.000416	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—testicular cancer	8.94e-05	0.000406	CcSEcCtD
Imipramine—ADRA1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	8.86e-05	0.0094	CbGpPWpGaD
Imipramine—SLC22A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	8.72e-05	0.00925	CbGpPWpGaD
Imipramine—Nausea—Epirubicin—testicular cancer	8.68e-05	0.000394	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—testicular cancer	8.6e-05	0.00039	CcSEcCtD
Imipramine—Rash—Doxorubicin—testicular cancer	8.52e-05	0.000387	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—testicular cancer	8.52e-05	0.000387	CcSEcCtD
Imipramine—Headache—Doxorubicin—testicular cancer	8.47e-05	0.000385	CcSEcCtD
Imipramine—CYP2C18—Biological oxidations—HPGDS—testicular cancer	8.19e-05	0.00868	CbGpPWpGaD
Imipramine—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	8.17e-05	0.00867	CbGpPWpGaD
Imipramine—Nausea—Doxorubicin—testicular cancer	8.03e-05	0.000365	CcSEcCtD
Imipramine—HTR6—GPCR ligand binding—INSL3—testicular cancer	7.95e-05	0.00843	CbGpPWpGaD
Imipramine—HTR7—GPCR ligand binding—INSL3—testicular cancer	7.94e-05	0.00842	CbGpPWpGaD
Imipramine—ADRA1B—AMPK Signaling—STK11—testicular cancer	7.85e-05	0.00833	CbGpPWpGaD
Imipramine—HTR1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.73e-05	0.00819	CbGpPWpGaD
Imipramine—HTR2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.69e-05	0.00815	CbGpPWpGaD
Imipramine—CHRM4—GPCR ligand binding—INSL3—testicular cancer	7.5e-05	0.00795	CbGpPWpGaD
Imipramine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.36e-05	0.0078	CbGpPWpGaD
Imipramine—CHRM5—GPCR ligand binding—INSL3—testicular cancer	7.18e-05	0.00761	CbGpPWpGaD
Imipramine—ADRA1A—AMPK Signaling—STK11—testicular cancer	6.97e-05	0.00739	CbGpPWpGaD
Imipramine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	6.81e-05	0.00722	CbGpPWpGaD
Imipramine—SLC6A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.78e-05	0.00719	CbGpPWpGaD
Imipramine—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.78e-05	0.00719	CbGpPWpGaD
Imipramine—ADRA1D—GPCR ligand binding—INSL3—testicular cancer	6.75e-05	0.00716	CbGpPWpGaD
Imipramine—HTR2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.67e-05	0.00708	CbGpPWpGaD
Imipramine—HRH1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.66e-05	0.00706	CbGpPWpGaD
Imipramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.64e-05	0.00704	CbGpPWpGaD
Imipramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.62e-05	0.00702	CbGpPWpGaD
Imipramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.55e-05	0.00695	CbGpPWpGaD
Imipramine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.54e-05	0.00693	CbGpPWpGaD
Imipramine—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	6.37e-05	0.00675	CbGpPWpGaD
Imipramine—SLC6A3—Transmembrane transport of small molecules—SLC2A6—testicular cancer	6.01e-05	0.00637	CbGpPWpGaD
Imipramine—HTR1A—GPCR ligand binding—INSL3—testicular cancer	5.88e-05	0.00624	CbGpPWpGaD
Imipramine—HTR2C—GPCR ligand binding—INSL3—testicular cancer	5.85e-05	0.00621	CbGpPWpGaD
Imipramine—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	5.6e-05	0.00594	CbGpPWpGaD
Imipramine—SLC22A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.47e-05	0.0058	CbGpPWpGaD
Imipramine—CYP3A7—Biological oxidations—HPGDS—testicular cancer	5.44e-05	0.00577	CbGpPWpGaD
Imipramine—DRD2—GPCR ligand binding—INSL3—testicular cancer	5.17e-05	0.00548	CbGpPWpGaD
Imipramine—SLC22A1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.1e-05	0.0054	CbGpPWpGaD
Imipramine—CHRM3—Integration of energy metabolism—STK11—testicular cancer	5.09e-05	0.00539	CbGpPWpGaD
Imipramine—HTR2A—GPCR ligand binding—INSL3—testicular cancer	5.08e-05	0.00539	CbGpPWpGaD
Imipramine—HRH1—GPCR ligand binding—INSL3—testicular cancer	5.07e-05	0.00538	CbGpPWpGaD
Imipramine—CHRM1—GPCR ligand binding—INSL3—testicular cancer	5.06e-05	0.00536	CbGpPWpGaD
Imipramine—CHRM3—GPCR ligand binding—INSL3—testicular cancer	5.04e-05	0.00534	CbGpPWpGaD
Imipramine—CHRM2—GPCR ligand binding—INSL3—testicular cancer	4.99e-05	0.00529	CbGpPWpGaD
Imipramine—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	4.98e-05	0.00528	CbGpPWpGaD
Imipramine—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	4.66e-05	0.00495	CbGpPWpGaD
Imipramine—HTR6—GPCR downstream signaling—INSL3—testicular cancer	4.49e-05	0.00476	CbGpPWpGaD
Imipramine—HTR7—GPCR downstream signaling—INSL3—testicular cancer	4.49e-05	0.00476	CbGpPWpGaD
Imipramine—CHRM4—GPCR downstream signaling—INSL3—testicular cancer	4.24e-05	0.00449	CbGpPWpGaD
Imipramine—HTR6—Signaling by GPCR—INSL3—testicular cancer	4.08e-05	0.00433	CbGpPWpGaD
Imipramine—HTR7—Signaling by GPCR—INSL3—testicular cancer	4.07e-05	0.00432	CbGpPWpGaD
Imipramine—CHRM5—GPCR downstream signaling—INSL3—testicular cancer	4.06e-05	0.0043	CbGpPWpGaD
Imipramine—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	4.05e-05	0.0043	CbGpPWpGaD
Imipramine—CYP2B6—Biological oxidations—HPGDS—testicular cancer	4.03e-05	0.00427	CbGpPWpGaD
Imipramine—CYP2E1—Biological oxidations—HPGDS—testicular cancer	3.94e-05	0.00418	CbGpPWpGaD
Imipramine—CHRM4—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	3.9e-05	0.00414	CbGpPWpGaD
Imipramine—CHRM4—Signaling by GPCR—INSL3—testicular cancer	3.85e-05	0.00408	CbGpPWpGaD
Imipramine—ADRA1D—GPCR downstream signaling—INSL3—testicular cancer	3.81e-05	0.00405	CbGpPWpGaD
Imipramine—CHRM5—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	3.74e-05	0.00396	CbGpPWpGaD
Imipramine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	3.72e-05	0.00394	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—INSL3—testicular cancer	3.68e-05	0.00391	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—INSL3—testicular cancer	3.46e-05	0.00367	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	3.32e-05	0.00353	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	3.31e-05	0.00351	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	3.17e-05	0.00336	CbGpPWpGaD
Imipramine—CYP2C19—Biological oxidations—HPGDS—testicular cancer	3.04e-05	0.00323	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—INSL3—testicular cancer	3.02e-05	0.0032	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—INSL3—testicular cancer	3e-05	0.00319	CbGpPWpGaD
Imipramine—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.99e-05	0.00317	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—INSL3—testicular cancer	2.92e-05	0.0031	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	2.88e-05	0.00305	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	2.87e-05	0.00305	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—INSL3—testicular cancer	2.87e-05	0.00304	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—INSL3—testicular cancer	2.86e-05	0.00303	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—INSL3—testicular cancer	2.85e-05	0.00302	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—INSL3—testicular cancer	2.82e-05	0.00299	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	2.81e-05	0.00298	CbGpPWpGaD
Imipramine—CYP2D6—Biological oxidations—HPGDS—testicular cancer	2.8e-05	0.00297	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.73e-05	0.0029	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—INSL3—testicular cancer	2.65e-05	0.00281	CbGpPWpGaD
Imipramine—CHRM1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	2.63e-05	0.00279	CbGpPWpGaD
Imipramine—CHRM3—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	2.62e-05	0.00278	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—INSL3—testicular cancer	2.61e-05	0.00277	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—INSL3—testicular cancer	2.6e-05	0.00276	CbGpPWpGaD
Imipramine—CHRM2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	2.6e-05	0.00275	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—INSL3—testicular cancer	2.59e-05	0.00275	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—INSL3—testicular cancer	2.59e-05	0.00274	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—INSL3—testicular cancer	2.56e-05	0.00272	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	2.55e-05	0.00271	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—INSL3—testicular cancer	2.41e-05	0.00256	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—INSL3—testicular cancer	2.41e-05	0.00255	CbGpPWpGaD
Imipramine—CYP1A2—Biological oxidations—HPGDS—testicular cancer	2.37e-05	0.00251	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—INSL3—testicular cancer	2.27e-05	0.00241	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—INSL3—testicular cancer	2.18e-05	0.00231	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—INSL3—testicular cancer	2.05e-05	0.00217	CbGpPWpGaD
Imipramine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.98e-05	0.0021	CbGpPWpGaD
Imipramine—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.83e-05	0.00194	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—INSL3—testicular cancer	1.78e-05	0.00189	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—INSL3—testicular cancer	1.77e-05	0.00188	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—INSL3—testicular cancer	1.7e-05	0.0018	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—INSL3—testicular cancer	1.57e-05	0.00166	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—INSL3—testicular cancer	1.54e-05	0.00163	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—INSL3—testicular cancer	1.54e-05	0.00163	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—INSL3—testicular cancer	1.53e-05	0.00163	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—INSL3—testicular cancer	1.53e-05	0.00162	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—INSL3—testicular cancer	1.51e-05	0.0016	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—INSL3—testicular cancer	1.51e-05	0.0016	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—HPGDS—testicular cancer	1.48e-05	0.00157	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—HPGDS—testicular cancer	1.4e-05	0.00149	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.17e-05	0.00124	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—STK11—testicular cancer	1.08e-05	0.00114	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—STK11—testicular cancer	1.02e-05	0.00108	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—HPGDS—testicular cancer	9.31e-06	0.000987	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—HPGDS—testicular cancer	9.3e-06	0.000986	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	9.1e-06	0.000965	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—HPGDS—testicular cancer	8.66e-06	0.000919	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—HPGDS—testicular cancer	8e-06	0.000849	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—H2AFZ—testicular cancer	7.71e-06	0.000818	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—H2AFZ—testicular cancer	7.7e-06	0.000817	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—STK11—testicular cancer	7.67e-06	0.000813	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—STK11—testicular cancer	7.66e-06	0.000812	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—H2AFZ—testicular cancer	7.28e-06	0.000772	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—STK11—testicular cancer	7.23e-06	0.000767	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KITLG—testicular cancer	7.1e-06	0.000752	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KITLG—testicular cancer	7.09e-06	0.000752	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—H2AFZ—testicular cancer	6.97e-06	0.000739	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—STK11—testicular cancer	6.93e-06	0.000735	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—HPGDS—testicular cancer	6.88e-06	0.00073	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—STK11—testicular cancer	6.76e-06	0.000717	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—STK11—testicular cancer	6.75e-06	0.000716	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—HPGDS—testicular cancer	6.74e-06	0.000715	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KITLG—testicular cancer	6.69e-06	0.00071	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—H2AFZ—testicular cancer	6.55e-06	0.000695	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—STK11—testicular cancer	6.51e-06	0.000691	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KITLG—testicular cancer	6.41e-06	0.00068	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—STK11—testicular cancer	6.29e-06	0.000668	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KITLG—testicular cancer	6.03e-06	0.000639	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—STK11—testicular cancer	5.81e-06	0.000617	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	5.71e-06	0.000605	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	5.68e-06	0.000602	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—STK11—testicular cancer	5.68e-06	0.000602	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—STK11—testicular cancer	5.65e-06	0.000599	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	5.44e-06	0.000577	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—STK11—testicular cancer	5.41e-06	0.000573	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—FGFR3—testicular cancer	5.27e-06	0.000559	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—FGFR3—testicular cancer	5.27e-06	0.000559	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KITLG—testicular cancer	5.25e-06	0.000557	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KITLG—testicular cancer	5.23e-06	0.000554	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—HPGDS—testicular cancer	5.2e-06	0.000552	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—HPGDS—testicular cancer	5.08e-06	0.000539	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—H2AFZ—testicular cancer	5.01e-06	0.000532	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—STK11—testicular cancer	5e-06	0.000531	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KITLG—testicular cancer	5e-06	0.00053	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—STK11—testicular cancer	4.98e-06	0.000529	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—FGFR3—testicular cancer	4.97e-06	0.000528	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	4.93e-06	0.000523	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—H2AFZ—testicular cancer	4.92e-06	0.000522	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—H2AFZ—testicular cancer	4.91e-06	0.00052	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—STK11—testicular cancer	4.9e-06	0.00052	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—STK11—testicular cancer	4.9e-06	0.00052	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—STK11—testicular cancer	4.89e-06	0.000519	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—H2AFZ—testicular cancer	4.89e-06	0.000519	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—STK11—testicular cancer	4.88e-06	0.000517	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—STK11—testicular cancer	4.86e-06	0.000516	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—H2AFZ—testicular cancer	4.84e-06	0.000514	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KIT—testicular cancer	4.84e-06	0.000513	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KIT—testicular cancer	4.84e-06	0.000513	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	4.83e-06	0.000512	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—STK11—testicular cancer	4.81e-06	0.000511	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—STK11—testicular cancer	4.8e-06	0.000509	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—HPGDS—testicular cancer	4.79e-06	0.000507	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—FGFR3—testicular cancer	4.76e-06	0.000505	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KITLG—testicular cancer	4.61e-06	0.000489	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KIT—testicular cancer	4.57e-06	0.000484	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KITLG—testicular cancer	4.54e-06	0.000481	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KITLG—testicular cancer	4.53e-06	0.00048	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KITLG—testicular cancer	4.51e-06	0.000479	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KITLG—testicular cancer	4.5e-06	0.000477	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—FGFR3—testicular cancer	4.48e-06	0.000475	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KITLG—testicular cancer	4.46e-06	0.000472	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KITLG—testicular cancer	4.44e-06	0.000471	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KIT—testicular cancer	4.37e-06	0.000464	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KIT—testicular cancer	4.11e-06	0.000436	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—HPGDS—testicular cancer	4.05e-06	0.00043	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—FGFR3—testicular cancer	3.9e-06	0.000414	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—FGFR3—testicular cancer	3.88e-06	0.000412	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—STK11—testicular cancer	3.78e-06	0.000401	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	3.72e-06	0.000394	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—STK11—testicular cancer	3.69e-06	0.000391	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KIT—testicular cancer	3.58e-06	0.00038	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KIT—testicular cancer	3.57e-06	0.000378	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—STK11—testicular cancer	3.48e-06	0.000369	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—FGFR3—testicular cancer	3.43e-06	0.000363	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KIT—testicular cancer	3.41e-06	0.000362	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—FGFR3—testicular cancer	3.37e-06	0.000358	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—FGFR3—testicular cancer	3.37e-06	0.000357	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—FGFR3—testicular cancer	3.35e-06	0.000356	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—FGFR3—testicular cancer	3.34e-06	0.000355	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—FGFR3—testicular cancer	3.31e-06	0.000351	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	3.3e-06	0.00035	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KIT—testicular cancer	3.15e-06	0.000334	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—HPGDS—testicular cancer	3.13e-06	0.000332	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KIT—testicular cancer	3.1e-06	0.000328	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KIT—testicular cancer	3.09e-06	0.000328	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KIT—testicular cancer	3.08e-06	0.000327	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KIT—testicular cancer	3.07e-06	0.000326	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KIT—testicular cancer	3.04e-06	0.000322	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KIT—testicular cancer	3.03e-06	0.000322	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—STK11—testicular cancer	2.95e-06	0.000312	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—STK11—testicular cancer	2.27e-06	0.000241	CbGpPWpGaD
